22KIT
Dosing advice on an app
Diabetes insulin dosing enhanced through Hedia
and Glooko partnership regarding the Hedia
Diabetes Assistant.
Glooko, Inc. and Hedia have
launched an innovative
interoperable solution
designed to improve
diabetes management. The solution
integrates connected care, remote
patient monitoring, and digital
therapeutic technologies to provide
enhanced support for individuals
with Type 1 and Type 2 diabetes who
need advanced bolus insulin dosing.
A bolus is an additional dose of
insulin taken to manage a rise in
blood glucose levels, typically after
eating a meal or snack. Generally, to
correct high blood sugar, one unit
of insulin can reduce blood glucose
by 50 mg/dl. However, for those
with diabetes who do not use an
insulin pump, calculating the correct
bolus dose can be a challenging
task for both patients and their
healthcare providers.
Glooko, a digital health company,
has developed a solution to make this
process easier and more accurate.
The Glooko platform allows patients
to seamlessly share their diabetesrelated
data, such as blood glucose
readings, insulin doses, carbohydrate
intake, exercise activity, blood
pressure, and weight, with their
healthcare providers. This solution
enhances diabetes management by
providing comprehensive insights
into a patient's daily health activities,
making it easier to adjust treatment
plans and improve health outcomes.
Here to help
In partnership with Hedia, Glooko
is introducing the Hedia Diabetes
Assistant, which integrates with its
platform to provide personalised
insulin dose recommendations. This
integration ensures that patients
have real-time access to tailored
bolus calculations, supporting more
effective management of their
diabetes. By considering various
factors such as active insulin,
food intake, physical activity, and
blood glucose levels, the Hedia
Diabetes Assistant generates insulin
recommendations that will help
stabilise blood glucose levels and
simplify diabetes management.
This solution allows patients
who are not using pumps to manage
their insulin dosing effectively,
providing them with personalized
and actionable recommendations.
The goal is to reduce the complexity
of managing diabetes with multiple
daily injections and ensure that
patients can maintain consistent
blood glucose control.
This partnership also benefits
healthcare providers by giving them
enhanced visibility into their patients'
health data. With easy access to key
metrics such as blood glucose levels,
insulin doses, carbohydrate intake,
physical activity, and more, providers
can make more informed decisions
about a patient's treatment plan.
Personalized
innovation
Mike Alvarez, Chief Executive
Officer of Glooko, comments,
"We are very pleased to bring this
algorithm-driven, personalized
innovation to diabetes patients and
their healthcare teams through
our partnership with Hedia. With
extensive clinical data supporting
Hedia's efficacy, this solution
provides an alternative for those
unable to access insulin pumps,
ensuring more effective management
of MDI therapy."
Lars Christian Lund, Chief
Executive Officer of Hedia, adds,
"This joint offering is perfectly
aligned with Hedia's vision to
improve the quality of life for people
with diabetes and make the best
diabetes management tools available."
Russ Johannesson, CEO of Glooko
2018 to 2024, said at the time of the
initial deal, "We are very pleased
to partner with Hedia to offer this
algorithm-driven innovation for
personalized healthcare for diabetes
patients and their healthcare teams.
The robust clinical data supporting
Hedia's efficacy demonstrates this
could be a viable alternative for
patients who are not able to access
insulin pumps. This partnership
shows how interoperability
gives people with diabetes the
optimal tools available to ease the
management of their condition and